Photobiomodulation Helmet Treatments for Parkinson's Alzheimer's Disease

• Increased anxiety, depression, or apathy
• Exhibiting uncharacteristic behavior or aggression
• Lack of motivation to engage in activities or interact with others
• Unsteady gait or problems with balance
• Overall decline in physical health and mobility as the disease progresses

1,By extending through the skull, the 810nm wavelength supports the healing process for traumatic brain injuries and helps reduce prolonged nerve damage.

2,Utilizing the 810nm wavelength can provide relief for individuals experiencing severe depression and anxiety.

3,Within the mitochondria, cytochrome C oxidase captures near-infrared light.

4,Greater blood flow, heightened energy, protection for nerve cells, and diminished inflammation.

5,Used in the treatment of stroke, traumatic, neurodegenerative, and psychiatric diseases.

6,Exceptional quality at a much reduced cost.

7,Easy operation, perfect for use at home or in a clinical environment.

8,Offers treatment protocols at no additional cost.

9,Premier post-purchase service.

10. Brain Regions: 12 areas, each adjustable for intensity, frequency, and time.

11. Additional Features: Includes nasal and ear laser applicators, enhancing efficiency with remote control.

Powerful light-emitting diode (LED) bulbs deliver laser red/NIR light onto the forehead, where the light photons pass through the skull into brain tissue. While red LED light devices have been used in clinical trials for various brain conditions, the greatest results will come from near-infrared light, which delivers wavelengths that can effectively, and safely, absorb into the brain.

Mitochondria receiving energy from red light.The most profound effect of red light therapy, which is at the heart of the chain of events that stimulates healing, is improved cell functioning. In fact, many studies, including a joint effort between Case Western Reserve University and the University of Texas, confirm that mitochondrial dysfunction (low-energy cells) is one of the primary causes of Alzheimer's disease. In the published study, the authors state that when mitochondria are structurally and functionally damaged due to oxidative stress, they are early stage markers of the disease.

When red light is absorbed by the body, light photons interact with mitochondria inside cells, which are colloquially referred to as cellular "energy factories." This stimulates the mitochondria to produce more cellular fuel, which energizes cells.

A recently published pilot study explored the impact of home-based photobiomodulation (PBM) on cognitive and behaviOral functions, cerebral perfusion, and resting-state functional connectivity in eight dementia patients. The study involved four patients receiving transcranial PBM (tPBM) and four receiving usual care. PBM treatments were administered at home using the COZING-C320A device three times a week. Participants were evaluated using the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and the Neuropsychiatric Inventory (NPI) at the start of the study, as well as at 6 and 12 weeks. Additionally, arterial spin-labeled perfusion MRI and resting-state functional MRI were conducted at the beginning and at the 12-week mark. After 12 weeks, the tPBM group showed significant improvements in ADAS-cog scores (p = 0.007) and NPI scores (p = 0.03), along with enhanced cerebral perfusion (p < 0.03) and increased connectivity between the posterior cingulate cortex and lateral parietal nodes within the default-mode network.



Salehpour et al. documented the treatment of a single patient diagnosed with cognitive decline and olfactory dysfunction. The patient underwent twice-daily PBM therapy at home using three different wearable LED devices. During the first week, a prototype transcranial light helmet and a body pad with a mix of 635 nm and 810 nm LEDs were used. The body pad was placed on various areas of the lower back while the helmet was worn while seated. After the initial week, an intranasal LED device (10-Hz, 810 nm) was introduced and used in the left nostril twice daily. All three devices were used simultaneously for 25 minutes per session. The patient demonstrated substantial improvements, with the Montreal Cognitive Assessment score increasing from 18 to 24 and the Working Memory Questionnaire score improving from 53 to 10. Additionally, the patient's olfactory dysfunction was reversed, as confirmed by the Alberta Smell Test and peanut butter odor detection test. Quality-of-life measures improved, and caregiver stress was significantly reduced.